Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 11/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.38 |
| ▸ | BMP1 | P13497 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5428175 | 0.81 | TACR1 (0.52) | TACR1SERPINE1 | |
| SCHEMBL27385426 | 0.81 | TACR1 (0.42) | TACR1MEN1KMT2ASERPINE1 | |
| SCHEMBL20568862 | 0.79 | CETP (0.45) | TACR1CETPBMP1 | |
| SCHEMBL546112 | 0.79 | TACR1 (0.41) | TACR1MEN1KMT2ASERPINE1 | |
| SCHEMBL788092 | 0.74 | TACR1 (0.40) | TACR1 | |
| SCHEMBL30950869 | 0.74 | TACR1 (0.40) | TACR1 | |
| Hydrochloric Acid SCHEMBL5913029 | 0.72 | IDO1 (0.42) | TACR1 | |
| Hydrochloric Acid SCHEMBL787855 | 0.72 | IDO1 (0.42) | TACR1 | |
| SCHEMBL545967 | 0.71 | TACR1 (0.43) | TACR1MEN1KMT2A | |
| SCHEMBL6678261 | 0.71 | CETP (0.43) | TACR1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630778-A1 | NOVEL INHIBITORS OF MAP4K1 | Ichnos Sciences SA (CH) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215668-A1 | NOVEL INHIBITORS OF MAP4K1 | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-11-29 | — | — | WO | disclosed |